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Abstract
Background: Early initiation of pharmacotherapy in Parkinson’s disease (PD) is nowadays widely advocated by
experts since the delay of treatment has shown to be associated with a significant deterioration of health related
quality of life in affected patients. Due to marked advances in PD treatment during the last decades, physicians are
nowadays fortunately equipped with a variety of substances that can effectively ameliorate emerging motor
symptoms of the disease, among them levodopa, dopamine agonists and monoamine oxidase type B (MAO-B)
inhibitors. Despite numerous drug intervention trials in early PD, there is however still ongoing controversy among
neurologists which substance to use for the initial treatment of the disease.
Discussion: In multiple studies, MAO-B inhibitors, such as selegiline and rasagiline, have shown to provide mild
symptomatic effects, delay the need for levodopa, and to reduce the incidence of motor fluctuations.
Although their symptomatic efficacy is inferior compared to dopamine agonists and levodopa, MAO-B
inhibitors undoubtedly have fewer side effects and are easy to administer. In contrary to their competitors,
MAO-B inhibitors may furthermore offer a chance for disease modification, which so far remains a major
unmet need in the management of PD and eventually makes them ideal candidates for the early treatment of
the disease.
Summary: MAO-B inhibitors may constitute a preferable therapeutic option for early PD, mainly due to their
favourable safety profile and their putative neuroprotective capabilities. Since the symptomatic effects of MAO-B
inhibitors are comparatively mild, dopamine agonists and levodopa should however be considered for initial
treatment in those PD patients, in whom robust and immediate symptomatic relief needs to be prioritized.
Background
Parkinson’s disease (PD) is the second most common
neurodegenerative disease after Alzheimer’s disease
and estimated to affect about 1-2% of the population
over 65 years [1]. Early treatment of emerging symp-
toms is nowadays widely recommended, since PD
patients left untreated at diagnosis show a significant
worsening in their health related quality of life in com-
parison to those patients in whom treatment is
initiated at or soon after diagnosis [2]. Furthermore, it
has been proposed that early treatment of PD may be
associated with a correction of basal ganglia functional
abnormalities caused by dopaminergic cell loss and
dopamine deficiency and could therefore support
intrinsic physiological compensatory mechanisms dur-
ing the course of the disease [3].
Once PD has been diagnosed, physicians eventually
find themselves faced by the question, which substance
to choose for the initial treatment of the disease. Fortu-
nately, we are nowadays provided with a variety of sub-
stances that can effectively counteract the motor
symptoms of the disease, among them levodopa, dopa-
mine agonists and monoamine oxidase type B (MAO-B)
inhibitors. In the following synopsis, we would like to
address why MAO-B inhibitors could be preferred in
this situation and may constitute the best option for the
initial treatment of PD.
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MAO-B inhibitors provide mild symptomatic effects in
early PD
Several large-scale, randomized placebo-controlled clini-
cal trials have demonstrated that treatment with MAO-
B inhibitors leads to a symptomatic amelioration of
early PD [4-9]. For example, daily treatment with 10 mg
selegiline (N-Propargylmethamphetamine) in the Depre-
nyl and Tocopherol Antioxidative Therapy of Parkinson-
ism (DATATOP) study was associated with an
improvement of about 3 points on the total Unified Par-
kinson’s Disease Rating Scale (UPDRS) and 1.7 points
on the motor subscale of the UPDRS compared to pla-
cebo after 3 months [4]. Symptomatic effects of similar
extent have been observed with the second-generation
MAO-B inhibitor rasagiline (N-Propargyl-1[R]aminoin-
dan), which for example in the TVP-1012 in early
monotherapy for PD outpatients (TEMPO) study led to
an improvement of about 3 points on the total UPDRS
after 3 months at a daily dose of 1 mg per day [5].
Although it can be argued that the symptomatic effects
of MAO-B inhibitors may not reach a clinically mean-
ingful magnitude [10] and are clearly inferior in compar-
ison to those seen with modern dopamine agonists
[11-14] or even the gold-standard levodopa [15,16],
MAO-B inhibitors may still be good candidates for
initial PD treatment, since they are able to attenuate the
usually mild motor symptoms during the early phase of
PD, thereby facilitating the sparing of symptomatically
stronger agents for later stages of the disease, when the
magnitude of motor impairment ultimately requires
more robust symptomatic action. Indeed, multiple stu-
dies have successfully demonstrated that early treatment
with the MAO-B inhibitors selegiline or lazabemide is
capable to delay the need to start with levodopa in PD
patients [4,8,9,17-19]. Since long-term levodopa treat-
ment is known to be associated with motor complica-
tions, the levodopa-sparing effect of MAO-B inhibitors
is likely to be beneficial in the long run, although clini-
cal studies so far failed to prove an antidyskinetic effect
of MAO-B inhibition, which may have been due to wide
confidence intervals in these studies [20]. However, clin-
ical studies have demonstrated that primary treatment
with the MAO-B inhibitor selegiline reduces the inci-
dence of motor fluctuations compared to placebo [21]
as well as to levodopa treatment [22]. Similarly, initial
monotherapy with the dopamine agonists ropinirole and
pramipexole has shown to significantly decrease the
incidence of dyskinesias and to a lesser extent also
motor fluctuations [23,24]. However, this did not trans-
late into a benefit in terms of overall function or quality
of life in comparison to patients that were initially trea-
ted with levodopa [23,24], which somewhat argues
against a general preference of dopamine agonists over
other antiparkinsonian agents in the early stages of PD.
In summary, initial treatment with MAO-B inhibitors
provides a mild effect on motor symptoms in patients
with early PD, delays the need for levodopa, reduces the
incidence of motor fluctuations and may furthermore
turn out advantageous from a strategic perspective,
since it enables physicians to counteract emerging
symptoms of early PD without already utilizing the
strongest symptomatic options at the very beginning.
Due to their superior symptomatic efficacy, dopamine
agonists and levodopa should however be considered for
initial treatment particularly in those PD patients, who
require immediate and robust symptomatic control of
their motor symptoms.
MAO-B inhibitors are well tolerated
When PD patients are subjected to chronic pharmacolo-
gical treatment for the first time, side effects of the
initial therapy will have a major impact on their judge-
ment of antiparkinsonian agents and eventually also be
crucial for long-term adherence to PD treatment. Thus,
it seems wise to choose an antiparkinsonian agent for
initial treatment that provides both symptomatic efficacy
and an advantageous side-effect profile. The use of
dopamine agonists is often accompanied by adverse
events such as nausea, dizziness, somnolence, oedema
and hallucinations, which in long-term clinical studies
led to substantial drop rates of about 30 to 40% [23,25].
Although treatment with levodopa is considered to be
safe and well tolerated, comparative studies between
levodopa and dopamine agonists found similar drop
rates due to side effects in levodopa treated patients as
with dopamine agonists [23,25]. Furthermore, long-term
administration of levodopa is known to be associated
with motor complications, such as dyskinesia and wear-
ing-off [15,26], which argues against its early use in PD.
On the contrary, clinical studies have demonstrated
that MAO-B inhibitors are well tolerated and usually do
not cause substantial side effects [20]. Although the use
of selegiline has been associated with adverse events like
anorexia, nausea, dry mouth, dyskinesia, musculoskeletal
injuries, hallucinations, cardiac arrhythmias and ortho-
static hypotension, which may be due to an augmenta-
tion of dopaminergic activity or amphetamine
metabolites of selegiline [27-31], it is important to note
that a meta-analysis of placebo-controlled trials found
no difference in dropouts due to adverse events between
patients treated with selegiline and patients treated with
placebo [20]. This observation suggests that side effects
of selegiline are not substantial enough to cause patients
to end therapy. Especially at higher doses, selegiline
treatment may however harbour a potential risk for
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its metabolites metamphetamine and amphetamine are
also capable to inhibit peripheral MAO-A [33,34], which
is crucial for the metabolism of tyramine [35]. Before
initiating selegiline treatment, it is therefore advisable to
instruct patients to avoid excessive intake of tyramine-
rich foods, such as aged cheese, tap beer, red wine and
salami. It should also be noted that in the past there has
been some controversy about the safety of selegiline
after a study by the Parkinson’s Disease Research Group
of the United Kingdom had reported excess mortality in
patients subjected to a combined treatment with levo-
dopa and selegiline [36], which seemed to affect particu-
larly those individuals with postural hypotension,
frequent falls, confusion and dementia [37]. However,
later meta-analysis found no significant difference in
mortality between patients on MAO-B inhibitors and
control patients and instead confirmed their good toler-
ability [20]. The safety profile of conventional selegiline
may moreover be further improved by the use of its
orally disintegrating form, which due to improved bioa-
vailability can be administered at lower doses with com-
parable efficacy and produces lower concentrations of
potentially troublesome metamphetamine metabolites by
bypassing first-pass metabolism in the liver [38].
In contrast to selegiline, the second-generation MAO-
B inhibitor rasagiline is metabolized to aminoindan,
which is devoid of an amphetamine-like chemical scaf-
folding and is thus considered not to have vasoactive
properties. Indeed, clinical studies demonstrated good
tolerability of rasagiline treatment and found no differ-
ence in the frequency of cardiovascular and psychiatric
adverse events between rasagiline and placebo treated
patients [5,6,39,40]. The excellent side-effect profile of
rasagiline has been recently confirmed in the Attenua-
tion of Disease Progression with Azilect Given Once-
daily (ADAGIO) trial, which showed no significant dif-
ferences in adverse events between placebo-treated
patients and study participants subjected to daily treat-
ment with 1 mg or 2 mg rasagiline [7]. Moreover, a
recently published tyramine challenge study has demon-
strated that rasagiline selectively inhibits MAO-B and is
not associated with increased tyramine sensitivity at the
recommended daily dose of 1 mg [41].
Taken together, data from clinical trials is supportive
of good tolerability and safety of MAO-B inhibitors as
antiparkinsonian agents, which is a second argument for
their use in early PD. Caution should be exercised when
administering MAO-B inhibitors together with drugs
that increase sympathetic tone, such as ephedrine and
phenylephrine, in order to avert the risk of hypertensive
crisis. Moreover, concomitant treatment with serotiner-
gic analgesics, such as meperidine, tramadol, methadone
and propoxyphene, should be generally avoided in order
to prevent a serotonin syndrome [35]. Caution is also
advised when administering MAO-B inhibitors together
with antidepressants that increase serotonin levels, such
as selective serotonin reuptake inhibitors, imipraminics
and serotonin-norepinephrine uptake inhibitors,
although available studies suggest that the risk to cause
serotonin toxicity due to concomitant treatment with
antidepressants is rather low [42,43].
MAO-B inhibitors are easy to use
Whenever long-term administration of pharmacological
agents becomes necessary, physicians need to ensure
that the dosing regimen is not too complex in order to
be followed by patients, since non-compliance may
result in early discontinuation, underuse, overuse and
irregular ingestion of medication. Previous smaller stu-
dies have demonstrated that therapy adherence in PD
patients is suboptimal and approximates that reported
in other chronic diseases [44,45]. In a larger European
multi-center study initiated by Donald Grosset, we have
been recently examining drug adherence in 112 PD
patients for 4 weeks using electronic monitoring bottles,
which recorded the date and time of cap opening [46].
In this study, 12.5% of PD patients took less than 80%
of prescribed medication, which was associated with sig-
nificantly poorer motor function and mobility [46].
Although overall total adherence to PD treatment was
high, we observed considerable variation of medication
intake between days and often irregular timing of medi-
cation intake, which argues against an early use of levo-
dopa in PD, since inaccurate timing of levodopa intake
may result in pulsatile dopaminergic stimulation and
accelerate the development of motor complications [47].
Indeed, patients with motor fluctuations in our study
had significantly lower total and timing adherence than
nonfluctuators [46]. On the contrary, once daily drugs
had significantly better adherence when compared with
drugs prescribed more frequently, which strongly sup-
ports the usage of novel extended-release formulations
of dopamine agonists or of MAO-B inhibitors, whereas
the latter are additionally capable to provide a more sus-
tained and continuous stimulation of the post-synaptic
dopaminergic receptors by prolonging the half-life of
dopamine in the basal ganglia.
Another possible obstacle to regular medication intake
in PD patients may be dysphagia, which although more
common in advanced stages can also be observed in
early PD [48,49]. In patients with swallowing difficulties,
PD treatment may be initiated with the orally disinte-
grating form of selegiline, which is nowadays available
on the market as Otrasel
®,X i l o p a r
® and Zelapar
®.I n
contrast to conventional selegiline and other antiparkin-
sonian agents, orally disintegrating selegiline is refined
by lyophilisation using Zydis technology
® [50], which
Löhle and Reichmann BMC Neurology 2011, 11:112
http://www.biomedcentral.com/1471-2377/11/112
Page 3 of 7ensures rapid dissolving in the mouth and facilitates
pregastral (predominantly buccal) absorption. Patient
preference for orally disintegrating selegiline has been
evaluated in a single-dose, randomised, two-way cross-
over study in 148 PD patients, in which about 30% were
suffering from swallowing difficulties [51]. In this study,
PD patients who had been previously treated with 10
mg of conventional selegiline as adjunctive therapy were
transiently switched to a single dose of 5 mg of orally
disintegrating selegiline or a placebo fast-dissolving for-
mulation and asked for their preference. Most patients
(61%) liked the novel formulation of selegiline, which
was a significantly greater proportion than the null
hypothesis of 50% (p < 0.002). Moreover, 67% of the
patients with swallowing difficulties preferred orally dis-
integrating selegiline to conventional selegiline tablets
[51]. These results indicate that alongside parenteral
forms of dopamine agonists, such as transdermal rotigo-
tine and subcutaneous apomorphine, orally disintegrat-
ing selegiline might be a worthwhile option for
treatment in those PD patients, in whom swallowing dif-
ficulties already constitute a problem at the beginning of
the disease.
MAO-B inhibitors potentially have disease-modifying
capabilities
Despite marked advances in symptomatic treatment
during recent decades, clinical studies in PD patients
have so far failed to provide compelling proof for neuro-
protective capabilities in most antiparkinsonian agents
[52]. In the absence of disease-modifying therapies,
symptomatic treatment can only transiently compensate
for the progressive neurodegeneration in the nigrostria-
tal system and in non-mesencephalic brain regions,
which will eventually lead to motor fluctuations, dyski-
nesias and intolerable disability in most PD patients
[53]. Consequently, neuroprotective therapy that slows
or even stops disease progression is considered a major
unmet medical need in the treatment of PD [54].
Data from preclinical studies has redundantly sug-
gested that MAO-B inhibitors may have neuroprotective
properties. For example, previous studies demonstrated
that selegiline is able to block the development of 1-
methyl-4-phenyl-1,2,3,6-tetrahydropyridine(MPTP)-
induced neurotoxicity [55,56] and in vivo may protect
mesencephalic dopaminergic neurons from glutamate
receptor-mediated toxicity [57,58] and from toxicity
induced by glutathione depletion [59]. Similar results
were also obtained with rasagiline, which was found to
increase survival in dopaminergic neurons [60,61] and
to protect against neurotoxin-induced apoptotic cell
death in SH-SY5Y cells [62,63]. Subsequent studies in
animal models of PD also demonstrated in vivo that
pre-treatment with selegiline or rasagiline is capable to
markedly attenuate the behavioural deficits arising from
neurotoxic MPTP and 6-hydroxydopamine injections
[64,65], thereby nourishing further hope that MAO-B
inhibitors would also harbour disease-modifying capabil-
ities in the clinical setting.
One of the earliest clinical studies to examine neuro-
protective effects in MAO-B inhibitors has been the
Deprenyl (= selegiline) and Tocopherol Antioxidative
Therapy of Parkinson (DATATOP) trial, in which 800
patients with early PD were randomized to four treat-
ment arms: 1) tocopherol placebo and selegiline pla-
cebo, 2) 2000 IU tocopherol per day and selegiline
placebo, 3) tocopherol placebo and 10 mg selegiline per
day and 4) 2000 IU tocopherol and 10 mg selegiline per
day [4,66]. This study was prematurely terminated after
a mean of 12 months when an interim analysis revealed
that patients treated with selegiline required levodopa
nine months later than individuals who were not rando-
mized to selegiline treatment [66]. Although this delay
in the onset of disability necessitating levodopa therapy
was tempting to the conclusion that selegiline would be
neuroprotective and had also been found in similar stu-
dies [9,18], final analysis of the DATATOP study
demonstrated that the benefit of selegiline in delaying
disability was related to a symptomatic relief of PD [4].
Moreover, long-term observation of the study cohort
demonstrated that after an average of 8.2 years the mor-
tality rate was unaffected by selegiline treatment, thus
further questioning a putative disease-modifying effect
of this substance [67].
More promising results have been found with rasagi-
line, which has been investigated in two double-blind,
placebo-controlled clinical trials, which both utilized the
delayed-start design in order to separate potential neu-
roprotective properties of rasagiline from its sympto-
matic effects [6,7]. In the TVP-1012 in early
monotherapy for PD outpatients (TEMPO) study, 404
previously untreated patients with early PD were rando-
mized to one of three treatment groups: 1) 1 mg rasagi-
line per day for 1 year, 2) 2 mg rasagiline per day for 1
year or 3) placebo for 6 months followed by 2 mg rasa-
giline per day for 6 months. The difference between
early and delayed treatment on the total UPDRS after
one year was about 2 points, which cannot be purely
attributed to a symptomatic effect of rasagiline [6].
Moreover, results of an open-label extension of the
TEMPO study recently demonstrated that early rasagi-
line treatment in comparison to delayed treatment pro-
vided long-term clinical benefit over years even in the
face of treatment with other dopaminergic agents, which
can only be explained by an enduring neuroprotective
effect of rasagiline or an influence on compensatory
mechanisms in early PD [68]. Disease-modifying effects
of rasagiline have also been examined in the Attenuation
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(ADAGIO) study, which was performed in two phases,
each lasting 36 weeks [7]. In the first phase, 1176 sub-
jects were randomly assigned to one of four study
groups: rasagiline at a dose of either 1 mg or 2 mg per
day (the early-start groups) or corresponding placebo.
In the second phase, the early-start groups continued
to receive their assigned treatment while subjects in
the placebo groups were switched to rasagiline at a
dose of 1 mg or 2 mg per day (the delayed-start
groups). Three end points had to be met in hierarchi-
cal fashion in order to declare positive results, which
comprised 1) less worsening in the rate of change in
the total UPDRS score between weeks 12 and 36 as
compared with placebo, 2) less worsening in the total
UPDRS score between baseline and week 72 in the
early-start group than in the delayed-start group and
3) non-inferiority in the rate of worsening in the total
UPDRS score between weeks 48 and 72 in the early-
start group in comparison to the delayed-start group
[7]. Rasagiline at a dose of 1 mg per day met all three
pre-defined end points, which is consistent with a pos-
sible disease-modifying effect of this treatment. Sur-
prisingly, results were negative for patients treated
with rasagiline at a daily dose of 2 mg, since this dose
f a i l e dt om e e tt h es e c o n de n d p o i n t .H o w e v e r ,A D A -
GIO investigators hypothesized that symptomatic
effects of rasagiline 2 mg per day may have masked
disease-modifying effects in this population of patients
with very mild disease, which was supported by a post-
hoc subgroup analysis revealing that the second end-
point was indeed met in those subjects, who were in
the highest quartile of UPDRS scores at baseline [7].
Despite uncertainties arising from the ADAGIO study,
the functional significance of its results and putative
general concerns with the delayed-start design [69], it
is important to note that the clinical data on neuro-
protective effects of rasagiline are so far unrivalled in
comparison to trials with other antiparkinsonian
agents. Although previous studies have also suggested
neuroprotective properties for levodopa [15] and for
dopamine agonists [70,71] by using neuroimaging bio-
markers as surrogate endpoint for disease progression,
t h es i g n i f i c a n c eo ft h e s ef i n d i n g sr e m a i n sr a t h e rq u e s -
tionable due to methodological difficulties and poor
correlation between radiotracer imaging and the even-
tual clinical outcome [52,72]. On the contrary, the
long-term clinical benefit that has been observed in
the open-label extension of TEMPO eventually pro-
vides at least some scientific rationale for assuming
disease-modifying effects of rasagiline in early PD,
which may provide another good reason to favour
MAO-B inhibitors for the initial treatment of PD.
Summary
Despite ongoing controversies among neurologists on
how to initiate treatment in early PD there are compel-
ling arguments for MAO-B inhibitors to be preferred in
this situation. In clinical studies, they have shown to
ameliorate symptoms of the disease, to delay the need
for levodopa and to reduce the incidence of motor fluc-
tuations. Furthermore, MAO-B inhibitors come with no
substantial side effects and are easy to administer, which
facilitates long-term adherence of patients to the ther-
apy. In contrary to other antiparkinsonian agents such
as levodopa and dopamine agonists, there is moreover
growing and so far unrivalled clinical evidence for
potential disease-modifying effects of MAO-B inhibitors
i nP D ,w h i c hm a ye v e n t u a l l yo n l yb ef u l l ye x p l o i t e db y
an early application from the very beginning of the dis-
ease. On the contrary, it needs to be acknowledged that
the symptomatic efficacy of MAO-B inhibitors is clearly
inferior to those of dopamine agonists and levodopa,
which should be particularly considered if immediate
and robust control of motor symptoms is warranted. In
the future, head-to-head comparison of antiparkinsonian
agents (such as in the ongoing PD MED trial) may allow
an unbiased and patient-orientated assessment of the
risk-benefit relationship in individual PD medications
and eventually facilitate the decision on how to initiate
treatment in early PD.
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